Data-driven Antibody Engineering

April 25, 2016

Presented at PEGS, Boston, MA, USA

Biopharmaceuticals are the drugs of the future, but their generation, design, and engineering is complex and expensive. Gaining a better understanding of the factors behind the efficacy, expressibility, stability and immunogenicity of biopharmaceuticals is crucial to improve protein engineering and reduce development timelines and costs. Here we present a novel informatics platform for antibody screening, engineering, and production, that enables researchers to integrate and visualize sequence (CDR compositions, AA residue distribution, PTMs, etc.), expression (vector, expression system, titers, etc.), and characterization data (assays and analytics). We provide specific examples of effectively integrating and analyzing a complex data set to identify specific positional engineering targets and prioritize the most promising engineering candidates.



Back to list